Considering Interim Interventions to Control COVID-19 Associated Morbidity and Mortality – The Perspectives

11 Pages Posted: 27 Mar 2020 Last revised: 31 Mar 2020

See all articles by Mark Christopher Arokiaraj

Mark Christopher Arokiaraj

Pondicherry Institute of Medical Sciences - Cardiology

Date Written: March 27, 2020

Abstract

As coronavirus (COVID-19) disease is evolving rapidly, there is a growing need to discuss the elements of coordinated strategy to control the spread and mitigate the severity and mortality of COVID-19. Apart from confinement and sanitation measures, which are temporary, we need consider using existing and readily available medications for use. H1N1 vaccine and streptococcus pneumoniae vaccines are traditionally available. The current report discusses the possible methods for reduction in coronavirus related morbidity and mortality using these vaccine measures effectively as an inexpensive primary care strategy; before a dedicated vaccine for coronaviruses emerges for regular clinical use. A significant reduction in the need for intensive care unit admissions, ventilators, and thereby reducing mortality, would translate into considerable benefits in health care dynamics and the global economy.

Keywords: Coronavirus, COVID-19, influenza vaccine, pneumococcal vaccine, pathogenesis

JEL Classification: I, E

Suggested Citation

Arokiaraj, Mark Christopher, Considering Interim Interventions to Control COVID-19 Associated Morbidity and Mortality – The Perspectives (March 27, 2020). Available at SSRN: https://ssrn.com/abstract=3562102 or http://dx.doi.org/10.2139/ssrn.3562102

Mark Christopher Arokiaraj (Contact Author)

Pondicherry Institute of Medical Sciences - Cardiology ( email )

605014
India

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
138
Abstract Views
1,149
rank
224,541
PlumX Metrics